[{"id":"04b23f96-640c-4d7c-9c86-475db9834138","acronym":"","url":"https://clinicaltrials.gov/study/NCT06428500","created_at":"2024-05-25T04:08:06.513Z","updated_at":"2025-02-25T15:29:03.721Z","phase":"Phase 1","brief_title":"QTX3046 in Patients with KRAS G12D Mutations","source_id_and_acronym":"NCT06428500","lead_sponsor":"Quanta Therapeutics","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • QTX3046"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-10"}]